ruxolitinib tablets
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Polycythemia Vera
Conditions
Polycythemia Vera
Trial Timeline
Oct 27, 2010 → Feb 9, 2018
NCT ID
NCT01243944About ruxolitinib tablets
ruxolitinib tablets is a phase 3 stage product being developed by Novartis for Polycythemia Vera. The current trial status is completed. This product is registered under clinical trial identifier NCT01243944. Target conditions include Polycythemia Vera.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01243944 | Phase 3 | Completed |
Competing Products
20 competing products in Polycythemia Vera
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Sapablursen + Placebo | Ono Pharmaceutical | Phase 3 | 77 |
| Ruxolitinib + Abemaciclib | Eli Lilly | Phase 1 | 33 |
| Bomedemstat | Merck | Phase 2 | 52 |
| Ruxolitinib + Hydroxycarbamide + Interferon-Alpha | Novartis | Phase 3 | 77 |
| Ruxolitinib | Novartis | Pre-clinical | 23 |
| Ruxolitinib | Novartis | Phase 3 | 77 |
| Ruxolitinib + BAT | Novartis | Phase 2 | 52 |
| Hydroxyurea | Novartis | Approved | 85 |
| Best Available Therapy + Ruxolitinib | Novartis | Phase 3 | 77 |
| Smac Mimetic LCL161 | Novartis | Phase 2 | 52 |
| PEGASYS + Aspirin | Roche | Phase 2 | 52 |
| RG7388 + Pegasys | Roche | Phase 1 | 33 |
| Idasanutlin | Roche | Phase 2 | 52 |
| PEGASYS + Hydroxyurea + Aspirin | Roche | Phase 3 | 77 |
| Ropeginterferon alfa-2b | PharmaEssentia | Phase 2 | 51 |
| Pegylated-Proline-Interferon alpha-2b in a Pre-filled Pen | PharmaEssentia | Phase 3 | 76 |
| Pegylated-Proline-interferon alpha-2b + Best available therapy (BAT) | PharmaEssentia | Phase 3 | 76 |
| Ropeginterferon alfa-2b | PharmaEssentia | Approved | 84 |
| P1101 + Low-dose aspirin | PharmaEssentia | Phase 2 | 51 |
| P1101 (Ropeginterferon alfa-2b) | PharmaEssentia | Phase 3 | 76 |